Scott Dreyer Sells 49,976 Shares of Collegium Pharmaceutical (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer sold 49,976 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the sale, the executive vice president owned 71,770 shares in the company, valued at $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Scott Dreyer also recently made the following trade(s):

• On Monday, December 8th, Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $48.17, for a total value of $847,792.00.

Collegium Pharmaceutical Trading Up 0.0%

Collegium Pharmaceutical stock opened at $37.29 on Friday. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $50.79. The stock has a 50-day moving average price of $45.48 and a 200 day moving average price of $42.08. The stock has a market cap of $1.18 billion, a PE ratio of 21.81 and a beta of 0.67. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The firm had revenue of $205.45 million during the quarter, compared to analysts’ expectations of $206.36 million. During the same period in the previous year, the firm posted $1.77 earnings per share. The firm’s revenue was up 12.9% on a year-over-year basis. Equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on COLL shares. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday. Barclays reduced their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, January 9th. Finally, Wall Street Zen downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Group One Trading LLC acquired a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares during the period. Federated Hermes Inc. raised its holdings in shares of Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares during the last quarter. CWM LLC raised its holdings in shares of Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,153 shares during the last quarter. Finally, Hantz Financial Services Inc. boosted its position in shares of Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after buying an additional 993 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.